Rafael Ortiz

Dr. Rafael Ortiz

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2018 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
RORafael Ortiz
Rafael Ortiz
NLNathália Martins Lopes
Nathália Martins Lopes
NANadia Ghinelli Amôr
Nadia Ghinelli Amôr
JPJosé Burgos Ponce
José Burgos Ponce
CSCláudia Kliemann Schmerling
Cláudia Kliemann Schmerling
CRCamila Rodini
Camila Rodini

29 April 2024 in Journal of Clinical Periodontology
Verified
Journal Article
Closed access
PDF file
ABAna Carolina Cestari Bighetti
Ana Carolina Cestari Bighetti
TCTania Mary Cestari
Tania Mary Cestari
SPSuelen Paini
Suelen Paini
KPKarina Torres Pomini
Karina Torres Pomini
Daniela Vieira BuchaimDaniela Vieira Buchaim
Daniela Vieira Buchaim
GAGerson F. de Assis
Gerson F. de Assis

2 December 2023 in Cytokine
Verified
Journal Article
Closed access
LSLuciana Mieli Saito
Luciana Mieli Saito
RORafael Ortiz
Rafael Ortiz
NANádia Ghinelli Amôr
Nádia Ghinelli Amôr
NLNathália Martins Lopes
Nathália Martins Lopes
RBRodrigo Fonseca Buzo
Rodrigo Fonseca Buzo
CRCamila Rodini
Camila Rodini

8 May 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RORafael Ortiz
Rafael Ortiz
NANádia Ghinelli Amôr
Nádia Ghinelli Amôr
LSLuciana Mieli Saito
Luciana Mieli Saito
MSMariana Rodrigues Santesso
Mariana Rodrigues Santesso
NLNathália Martins Lopes
Nathália Martins Lopes
CRCamila Rodini
Camila Rodini
Identifying marker combinations for robust prognostic validation in primary tumour compartments remains challenging. We aimed to assess the prognostic significance of CSC markers (ALDH1, CD44, p75NTR, BMI-1) and E-cadherin biomarkers in OSCC. We analysed 94 primary OSCC and 67 metastatic lymph node samples, including central and invasive tumour fronts (ITF), along with clinicopathological data. We observed an increase in ALDH1+/CD44+/BMI-1- tumour cells in metastatic lesions compared to primary tumours. Multivariate analysis highlighted that elevated p75NTR levels (at ITF) and reduced E-cadherin expression (at the tumour centre) independently predicted metastasis, whilst ALDH1high exhibited independent predictive lower survival at the ITF, surpassing the efficacy of traditional tumour staging. Then, specifically at the ITF, profiles characterized by CSChighE-cadherinlow (ALDH1highp75NTRhighE-cadherinlow) and CSCintermediateE-cadherinlow (ALDH1 or p75NTRhighE-cadherinlow) were significantly associated with worsened overall survival and increased likelihood of metastasis in OSCC patients. In summary, our study revealed diverse tumour cell profiles in OSCC tissues, with varying CSC and E-cadherin marker patterns across primary tumours and metastatic sites. Given the pivotal role of reduced survival rates as an indicator of unfavourable prognosis, the immunohistochemistry profile identified as CSChighE-cadherinlow at the ITF of primary tumours, emerges as a preferred prognostic marker closely linked to adverse outcomes in OSCC.

1 January 2023 in Journal of Applied Oral Science
Verified
Journal Article
Open access
PDF file
RORafael Ortiz
Rafael Ortiz
GGGabriele Gomes Gois
Gabriele Gomes Gois
CCCamila Alves Costa
Camila Alves Costa
NCNádia Lago Costa
Nádia Lago Costa
CRCamila Rodini
Camila Rodini
Lip squamous cell carcinoma (LSCC) accounts for 12% of all head and neck cancers. It is caused by chronic exposure to ultraviolet light solar radiation and related to previous actinic cheilitis (AC). This study aimed to investigate the immunostaining of the putative cancer stem cells (CSC) markers ALDH1 and CD44 in AC (n=30) and LSCC (n=20). ALDH1 positivity was found to be statistically higher in LSCC than in AC lesions (p=0.0045), whilst CD44 expression was statistically higher in AC than in LSCC lesions (p=0.0155). ALDH1+ cells in AC lesions were associated with specific clinical features: a younger age (<60 years old), the female gender, white skin, not smoking or consuming alcohol, and a fast evolution, and not associated with the chronic exposure to UV radiation (p<0.0001). CD44 positivity was associated with patients who were male, feoderm, smoked, consumed alcohol, underwent occupational exposure to UV-radiation, and demonstrated lesions with log-time evolution (p<0.0001). ALDH1 + cells were associated with mild dysplasia using a system from the World Health Organization (WHO), and with a low risk of malignant transformation, according to the binary system (p<0.0001). CD44+ cells were also associated with moderated dysplasia, according to the WHO system. In LSCC, ALDH1 + cells were positively associated with patients who were older (≥ 60 years old), smokers, and with those who consumed alcohol (p<0.0001). CD44 + cells in LSCC were associated with older (≥ 60 years old) patients as well, but also with female patients, white skin, non-smokers, and individuals who did not consume alcohol (p<0.0001), all of whom showed distinct patterns in pre- and malignant lesions of both markers. Additionally, in LSCC, both ALDH1 and CD44 staining were associated with smaller tumor sizes (T1/T2; p<0.0001). In summary, although both ALDH1 and CD44 were associated with the presence of dysplasia in AC lesions, the present findings suggest that ALDH1 and CD44 may be activated by different etiopathogenic pathways, predominantly in distinct steps of oral carcinogenesis. CD44 would thus be more significantly related to the potentially malignant lesion, while ALDH1 would be closely linked to malignancy.

21 January 2025 in Biology
Verified
Journal Article
Open access
PDF file
AFAngélica Fonseca
Angélica Fonseca
PCPriscila Maria Colavite
Priscila Maria Colavite
MAMichelle de Campos Soriani Azevedo
Michelle de Campos Soriani Azevedo
DPDaniela Carignatto Passadori
Daniela Carignatto Passadori
JMJéssica Lima Melchiades
Jéssica Lima Melchiades
GGGustavo Garlet
Gustavo Garlet
Dental socket repair theoretically involves a constructive inflammatory immune response, which evolves from an initial M1 prevalence to a subsequent M2 dominance. In this scenario, the MEK1/2 signaling pathway is allegedly involved in M2 polarization. This study aimed to evaluate the impact of MEK1/2 pharmacological inhibition in the local host response and repair outcome. C57Bl/6-WT 8-week-old male mice were submitted to the extraction of the right upper incisor and treated (or not, control group) with MEK1/2 inhibitor PD0325901 (10 mg/kg/24 h/IP, MEK1/2i group) and analyzed at 0, 3, 7, and 14 days using microcomputed tomography, histomorphometry, birefringence, immunohistochemistry, and PCR array analysis. The results demonstrate that MEK1/2 inhibition limits the development of M2 response over time, being associated with lower expression of M2, MSCs, and bone markers, lower levels of growth and osteogenic factors, along with a higher expression of iNOS, IL-1b, IL-6, and TNF-α, as well inflammatory chemokines, indicating a predominantly M1 pro-inflammatory environment. This modulation of local inflammatory immune response is associated with impaired bone formation as demonstrated by microtomographic and histomorphometric data. The results show that MEK1/2 inhibition delays bone repair after tooth extraction, supporting the concept that M2 macrophages are essential elements for host response regulation and proper repair.